Project Grant R21HL186766
Award Date 8/1/26
Completion Date 6/30/28
Dollars Obligated $240K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded The Washington University $550,896 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop targeted nanotherapy for acute myocardial infarction. The project, led by Principal Investigator Jianjun Guan, will encapsulate an engineered secretome derived from naive M0 macrophages into nanoparticles for intravenous administration to simultaneously address three critical post-infarction pathologies:...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $248,999 to The University of Iowa on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support fate-mapping of cardiac monocyte recruitment and specification. The award funds research investigating how diverse macrophage populations obtain their distinct transcriptional profiles following cardiac injury, with the goal of identifying spatiotemporal dynamics of macrophage recruitment...
- The National Heart, Lung, and Blood Institute awarded the University of California, Davis $590,503 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on cardiac regenerative therapy using gene-edited stem cells to improve transplantation outcomes in end-stage heart failure. The research addresses inflammation-mediated cell death that impedes cardiac stem cell therapy by modifying both donor cells and the host environment to target genes...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the J. David Gladstone Institutes $1,569,656 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate chromatin regulation of immune cells in myocardial inflammation, with performance through May 31, 2030. The project elucidates BRD4-mediated chromatin and gene regulatory networks controlling monocyte differentiation and macrophage function during myocardial infarction, with the goal of...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $799,256 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac protection through neuromodulation after myocardial infarction. The project, designated R01HL183128, will conduct research on the interplay between cardiac injury signals, brain integration, and peripheral sympathetic outflow following myocardial infarction. The work spans three...